Skip to content
S25S25S25

Drawing based on the description in the official product monograph. No photo yet.

“25 mg film-coated tablets are pale yellow, oval, biconvex and debossed with "S25" on one side and the Boehringer Ingelheim logo on the other”

S25 pill

Pill with imprint S25 is yellow, oval and has been identified as Empagliflozin 25 mg. It is used for type 2 diabetes. It is supplied by Boehringer Ingelheim (Canada) Ltd Ltee.

Sold in Canada

Empagliflozin 25 mg

Brand
Jardiance
Imprint
S25
Strength
25 mg
Used for
Type 2 diabetes
Color
Yellow
Shape
Oval
Form
Tablet
Manufacturer
Boehringer Ingelheim (Canada) Ltd Ltee
Drug class
Diabetes medicine (SGLT2 inhibitor)
Sold in
Canada
DIN
02443945

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Empagliflozin pills and guides

What is Empagliflozin used for?

Empagliflozin is used for type 2 diabetes.

Medicine type
Diabetes medicine (SGLT2 inhibitor)
Official uses from the US prescribing label

JARDIANCE is indicated:

  • to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
  • to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
  • to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
  • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

Limitations of Use

JARDIANCE is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.

JARDIANCE is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m 2. JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action.

JARDIANCE is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. JARDIANCE is not expected to be effective in these populations.

From the FDA-approved label on DailyMed (published Aug 27, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows S25.
  • It is yellow, oval.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Jardiance by Boehringer Ingelheim (Canada) Ltd Ltee.

In Canada: prescription only.

Ingredients

Active: Empagliflozin

Other pills with imprint S 25

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Empagliflozin pills